Table 4.
Adjusted incidence rates of hospitalization for acute liver injury
| CPRD | HIRD | Medicare | ||||
|---|---|---|---|---|---|---|
| Dapagliflozin | Comparator GLD | Dapagliflozin | Comparator GLD | Dapagliflozin | Comparator GLD | |
| Treatment episodes, n | 9027 | 32,455 | 15,217 | 175,107 | 11,332 | 172,986 |
| hALI events, n | < 5a | 20 | 14 | 172 | 13 | 189 |
| Person-years | ~ 11,000a | 28,950 | 10,315 | 91,740 | 6756 | 106,273 |
| Adjusted incidence rate (95% CI) per 1000 person-years | 0.37 (0.10–0.93) | 0.62 (0.27–1.11) | 1.36 (0.74–2.28) | 1.83 (1.55–2.15) | 1.92 (1.02–3.29) | 1.70 (1.42–2.02) |
CI confidence interval, CPRD Clinical Practice Research Datalink, GLD glucose-lowering drug, hALI hospitalization for acute liver injury, HIRD HealthCore Integrated Research Database
aAccording to CPRD policy, any cell with a value of 1 to 4 or any cell that allows a value of 1 to 4 to be derived from other reported cells or information cannot be reported
Incidence rates were standardized across the propensity score strata within each exposure group. Then, for each exposure group, the stratum-specific incidence rate was calculated and standardized using the person-years in the dapagliflozin cohort to estimate the standardized incidence rate and variance